Vincent Loic A 4

What Happened Vincent Loic A, Chief Scientific Officer of Korro Bio, was granted a derivative award on Feb 2, 2026: an option-like grant for 35,000 shares (reported price $0.00). This was an award/acquisition (not an open-market purchase or sale) and carries a vesting schedule rather than representing immediately tradable shares.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (appears timely).
• Security: Derivative award (option) for 35,000 shares; reported price per share: $0.00.
• Vesting: The award vests in 48 equal monthly installments commencing Feb 2, 2026 (footnote).
• Shares owned after transaction: Not specified in the provided filing.
• No indication of a 10b5-1 plan, cashless exercise, tax-withholding sale, or gift in the filing.

Context This was a compensation-related option grant that vests over four years — a common structure for employee retention. Because it is an award (not a purchase or sale), it does not by itself signal immediate buying or selling by the insider; the shares will only become owned/transferable as they vest and any future exercises or sales would be reported separately.